A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Clinical trial NCT07183189 · RECRUITING

Trial details

NCT number: NCT07183189
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2025-10-30
Primary completion: 2032-11-01
Enrollment: 576

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.